Loading clinical trials...
Loading clinical trials...
An Open-Label, Multi-Cohort, Multi-center, Non-Randomized, Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
Conditions
Interventions
MRG003
Locations
1
China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Start Date
September 4, 2020
Primary Completion Date
December 1, 2022
Completion Date
February 1, 2023
Last Updated
April 9, 2021
NCT04165798
NCT06667908
NCT06875310
NCT07046923
NCT07222566
NCT06667076
Lead Sponsor
Shanghai Miracogen Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions